Elanco Animal HealthELAN +3.36%66 EBITDA Margin % is 23.05% as of Mar. 2026, which is 106% above its 10-year median of 11.17. GuruFocus rates ELAN with a GF Score™ of 66/100 and a GF Value™ of $15.57 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Elanco Animal Health ranks better than 56.34% on this metric.
Elanco Animal Health (NYSE:ELAN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Elanco Animal Health EBITDA Margin % Related Terms
Elanco Animal Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Elanco Animal Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELAN vs RGC, NBIX, ALKS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elanco Animal Health EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Elanco Animal Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elanco Animal Health (ELAN) has a EBITDA Margin % of 23.05% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elanco Animal Health and its competitors. This is 106% above median its historical median of 11.17. According to the industry distribution chart, Elanco Animal Health ranks #417 out of 955 companies in the Drug Manufacturers industry, placing it in the top 43.7%.
Is Elanco Animal Health's EBITDA Margin % too high?
Elanco Animal Health's current EBITDA Margin % of 23.05% is 106% above median its 10-year median of 11.17. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Elanco Animal Health's value of 23.05% is 86% above this industry median. Based on the distribution chart, Elanco Animal Health ranks #417 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Elanco Animal Health has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's EBITDA Margin % compare to RGC and NBIX?
According to the Drug Manufacturers industry distribution chart, Elanco Animal Health ranks #417 out of 955 companies for EBITDA Margin %. This puts Elanco Animal Health in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Elanco Animal Health's value of 23.05% is 86% above this benchmark. While the company's 10-year median is 11.17 vs. the industry median of 12.39, Elanco Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elanco Animal Health's current EBITDA Margin % of 23.05% is 86% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elanco Animal Health and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elanco Animal Health's current EBITDA Margin % is 23.05%, which is 106% above median its own 10-year median of 11.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Elanco Animal Health (ELAN) is currently considered Significantly Overvalued. The stock's GF Value™ is $15.57, compared to a current price of $23.96 — trading 53.9% above its estimated fair value. The current EBITDA Margin % is 23.05%, which is 106% above median its 10-year median of 11.17 and 86% above the Drug Manufacturers industry median of 12.39. Elanco Animal Health's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Elanco Animal Health (ELAN), the current EBITDA Margin % is 23.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elanco Animal Health (ELAN) Overvalued in 2026?
Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued.
The current stock price of $23.96 is trading 53.9% above its estimated GF Value™ of $15.57.
GuruFocus considers Elanco Animal Health to be Significantly Overvalued.
Key valuation signals for ELAN:
EBITDA Margin %: 23.05% (106% above median its 10-year median of 11.17)
GF Value™: $15.57 vs. price of $23.96 (53.9% above fair value)
Industry Position: 86% above the Drug Manufacturers median (#417 of 955)
No single metric tells the full story. See the ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
66GF Score
Get the complete analysis for ELAN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELAN has been successfully added to your 
